Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel, Carboplatin, and Radiation Followed by Surgery in Stage III NSCLC
NCT00238615Phase 2Terminated
- Sponsor
- Stanford University
- Start
- Mar 2003
- Primary completion
- Sep 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in non-small cell lung cancer (NSCLC), sponsored by Stanford University. Primary endpoint: Overall Survival at 2 years. Started Mar 2003; status: terminated.
02
Drugs
docetaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00238615.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00238615.